Kathryn Atkins, Author at Oncotarget

Oncotarget News

Figure 2: Histopathological evaluation of oral mucositis on days 4, 8, 12 and 15. (truncated)

Oncotarget | The Chromatographic Constitution of Andiroba Oil and its Healing Effects…

January 24, 2023

The andiroba extract in wounds provides acceleration in healing process, with increase of contraction rate and local re-epithelialization, resulting in the complete closure of wounds [52].” BUFFALO, NY- January... read more

Figure 3: STRO-001 showed potent cell killing activity on proliferating primary human B cells.

Oncotarget

Oncotarget | Targeting CD74 in B-cell Non-Hodgkin Lymphoma With Antibody-Drug Conjugate STRO-001

January 17, 2023

Taken together, these findings provide a strong rationale for potently and selectively targeting of CD74 in patients with B-NHL [B-cell non-Hodgkin lymphoma].” BUFFALO, NY- January 17, 2023 – A new... read more

Figure 7: Proposed mechanism of 15d-PMJ2-mediated apoptosis.

Oncotarget

Oncotarget | Calcium Signaling Induced by 15-deoxy-prostamide-J2 Promotes Cell Death by Activating…

January 12, 2023

The goal of the present study was to determine the therapeutic potential of 15d-PMJ2 against melanoma by gaining insight into molecular mechanisms underlying its apoptotic activity.”BUFFALO, NY- January 12,... read more

Figure 1: Demographic factors, comorbidities and therapy regime of the melanoma patients in percentage, age in years.

Oncotarget

Oncotarget | Impact of Covid-19 on Management of Patients With Metastatic Melanoma

January 11, 2023

In this study, we aimed to analyze our experience with patients suffering from Sars-CoV-2 infection while receiving treatment for metastatic melanoma.” BUFFALO, NY- January 11, 2023 – A new research... read more

Figure 4: Wnt pathway expression in tumors from NeuT/ATTAC mice.

Oncotarget

Oncotarget | Resistance of MMTV-NeuT/ATTAC Mice to Anti-PD-1 Immune Checkpoint Therapy is Associated With Macrophage Infiltration and Wnt Pathway Expression

January 5, 2023

One of the impediments to successful cancer therapy is the heterogeneity and cellular plasticity of the tumor and TME [22, 23].” BUFFALO, NY- January 5, 2023 – A new research... read more

Oncotarget

Oncotarget | Serum microRNAs as New Criteria for Referral to Early Palliative Care Services in Treatment-Naïve Advanced Cancer Patients

December 29, 2022

The most important finding was the development of an objective prediction model for patients admitted to a PCU within 6 months among treatment-naïve advanced cancer patients.” —BUFFALO, NY-... read more

Oncotarget

Oncotarget | Role of Pyrethroid Derivatives in Autophagy and Apoptosis Crosstalk Signaling and Potential Risk for Malignancies

December 28, 2022

Pyrethroid derivatives and related products exposure have revealed to intensify various ailments and adverse health consequence in the different age groups [...]” —BUFFALO, NY- December 28, 2022 – A new research... read more

Oncotarget

Oncotarget | Plasma Growth Hormone a Potential Biomarker of Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma Patients

December 22, 2022

In conclusion, our study demonstrate[s] that plasma GH represents a candidate biomarker for predicting treatment outcomes in patients with advanced HCC treated with Atezo/Bev.”—BUFFALO, NY- December 22,... read more

Oncotarget

Oncotarget | Combined Epigenetic and Immunotherapy for Blastic and Classical Mantle Cell Lymphoma

December 13, 2022

Here, we describe results using cladribine based combination epigenetic and immunotherapy in MCL [mantle cell lymphoma].”BUFFALO, NY- December 13, 2022 – A new research paper was published in Oncotarget's Volume... read more

Oncotarget

Oncotarget | Expression of p-STAT3 and c-Myc Correlates With P2-HNF4α Expression in Nonalcoholic Fatty Liver Disease (NAFLD)

December 6, 2022

In conclusion, our results suggest that STAT3 phosphorylation occurs in livers with NAFLD only in the subset with P2-HNF4α expression, and c-Myc expression is strongly correlated with STAT3 phosphorylation.”BUFFALO,... read more